Back to News

Categories: News | Published On: April 24, 2024 | Written by webadmin@biolojic.com |

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

Back to News
More News
  • Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
    Read More
  • Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.
    Read More
BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com